Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial

3613 Background: 5 year-survival after LMCRC resection is 30–35%. Folfiri and Folfox are standard regimens in MCRC. The triple combination Folfirinox as induction CT could improve tumor shrinkage and therefore could allow resection of LM in unresectable patients (pts). Methods: Based on a multidisciplinary consensus, unresectability is defined as follows: LM in right or left lobe in contact of controlateral liver pedicle; LM in contact of veina cava or involving 2 hepatic veins and in contact with the third; liver remaining mass less than 25–30% of functional liver; no initial forseen optimal resection, but susceptible to become resectable after shrinkage. Biweekly 48h-cycles (Cy): L-OHP 85 mg/m2, CPT-11 180 mg/m2, LV5FU were administered. An Independent Committee (IC) reviewed pts eligibility and RR. The primary endpoint was resectability R0 defined as R0= margin≥2mm, R1=margin<2mm, Ra= resection + either cryosurgery or radiofrequency. Results: Among 34 pts included, 25 were eligible as per IC. To date, ...